Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
196TiP - CheckMate 384: A phase 3b/4 dose-frequency optimization trial of nivolumab in advanced or metastatic NSCLC (ID 248)
12:30 - 13:00 | Author(s): G. Selvaggi
Nivolumab, an anti-programmed death-1 antibody, is approved for previously treated metastatic non-small cell lung cancer (NSCLC) and various other cancers. Based on efficacy and safety results, the approved dosing frequency is every 2 weeks (Q2W) until progression or discontinuation due to toxicity. CheckMate 153 evaluated nivolumab treatment (tx) duration and demonstrated improved outcomes with continuous tx; 1-year progression-free survival (PFS) rates were higher in patients who continued vs stopped tx after 1 year. As an alternative to stopping tx, reducing dosing frequency could optimize convenience during long-term nivolumab therapy while maintaining efficacy and safety; recent exposure-response modeling predicted the benefit–risk profile of nivolumab 480 mg every 4 weeks (Q4W) to be similar to 3 mg/kg Q2W. CheckMate 384, a randomized, open-label phase 3b/4 trial was designed to evaluate less frequent nivolumab dosing (480 mg Q4W vs 240 mg Q2W) in patients with advanced/metastatic NSCLC and prior nivolumab tx.
Eligible patients are adults with advanced/metastatic squamous or non-squamous NSCLC and Eastern Cooperative Oncology Group performance status 0–2 who received prior nivolumab 3 mg/kg Q2W or 240 mg Q4W for up to 12 months with a complete or partial response or stable disease confirmed by 2 consecutive assessments. Patients with untreated, symptomatic central nervous system metastases are not eligible. Patients are randomized 1:1 to receive intravenous nivolumab 240 mg Q2W or 480 mg Q4W. Randomization is stratified by histology and response to pre-study nivolumab tx (complete/partial response vs stable disease). Endpoints are shown in the Table. The primary objective is to compare 6-month and 1-year PFS rates between patients who received nivolumab 480 mg Q4W and those who received 240 mg Q2W. Planned enrollment is 620 patients.Table:Study endpoints
Clinical trial identification: NCT02713867; First posted: March 21, 2016
Primary Secondary PFS rates at 6 months and 1 year after randomization (co-primary) PFS rate at 1 year after randomization by tumor histology and by response to pre-study nivolumab before randomization PFS rate at 2 years after randomization Overall survival rate Safety and tolerability, as assessed by incidence and severity of adverse events
Clinical trial identification:
NCT02713867; First posted: March 21, 2016
Legal entity responsible for the study:
E. Garon: Research funding from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Merck, Novartis, and Pfizer. N. Reinmuth: Speaker and consulting honoraria and fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Hoffmann-La Roche, Lilly, MSD, Novartis, and Pfizer. R. Harris: Consultant for Bristol-Myers Squibb. P. Mitchell: Advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Merck Serono, and Roche; Received research funding from Merck Serono. Received honoraria and travel grants from Roche. J. Zhu, G. Selvaggi, S. Agrawal: Employee and shareholder of Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.